-

Kirby McInerney LLP Announces an Investigation of Shareholder Claims on Behalf of Teladoc Health, Inc. (TDOC) Investors

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Teladoc Health, Inc. (“Teladoc” or the “Company”) (NYSE: TDOC). The investigation concerns whether Teladoc has violated the federal securities laws and/or engaged in other unlawful business practices.

Teladoc is a global provider of virtual care, transforming the access, cost, and quality dynamics of health care delivery.

On April 27, 2022 Teladoc reported financial results for the three months ended March 31, 2022. Additionally, Teladoc lowered revenue guidance for the balance of the year. The Company had previously told the market at its analyst day in November 2021 that its revenues would grow by 28% year over year in 2022. Then, in February 2022, Teladoc again revised guidance upwards. On this news, the price of Teladoc shares declined by $22.48 per share, or approximately 40.15%, from $55.99 per share to close at $33.51 per share on April 28, 2022.

If you purchased or otherwise acquired Teladoc securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website: http://www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-371-6600
https://www.kmllp.com
investigations@kmllp.com

Kirby McInerney LLP

NYSE:TDOC

Release Versions

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-371-6600
https://www.kmllp.com
investigations@kmllp.com

More News From Kirby McInerney LLP

INVESTOR ALERT: Securities Class Action Filed Against Soleno Therapeutics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ:SLNO) securities during the period of March 26, 2025 through November 4, 2025, inclusive (“the Class Period”). If you suffered a loss on your Soleno investments, you have until May 5, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submit...

REMINDER: NuScale Power Corporation Investors With Significant Losses Must Act By April 20, 2026

NEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP reminds NuScale Power Corporation (“NuScale” or the “Company”) (NYSE:SMR) investors of the April 20, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as...

INVESTOR ALERT: Securities Class Action Filed Against Eos Energy Enterprises, Inc. – Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Eos Energy Enterprises, Inc. (“Eos” or the “Company”) (NASDAQ:EOSE) period of November 5, 2025 through February 26, 2026, inclusive (“the Class Period”). If you suffered a loss on your Eos investments, you have until May 5, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitted after this deadlin...
Back to Newsroom